focus -WSS

focus

author：comprehensive 2025-10-01 00:58:20 - browse：512

Researchers say they’ve been able to measure recovery from treatment-resistant depression through brain scans — a crucial step toward quantifying the impact of therapies on a condition whose progress is notoriously difficult to measure objectively. And that’s thanks to generative AI, they say.

In a small study published Wednesday — just 10 people with severe, treatment-resistant depression receiving deep brain stimulation therapy — researchers used the electrodes to record brain activity and later fed the scans into a homegrown artificial intelligence system that analyzed them for patterns. They found that it was possible to track patients’ recovery through changes in brain cells’ electrical activity.

Finding so-called biomarkers, or objective measurements reflecting depression, could help diagnose depression, track its progression, predict a relapse, and better tailor therapies to individual patients. But finding those metrics has been difficult, partly because depression’s biological impact isn’t well understood.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： The inclusion problem at the heart of rehabilitation research

WSS

Pregnancy discrimination could be enabled by AI

Head of FDA's diagnostics center, who led through Covid, retires

FDA approves world's first CRISPR

Why sickle cell disease is getting the first CRISPR treatment

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

After sickle

leisure time

focus

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Flu vaccine reformulation won't be easy, manufacturers warn

Continuity nursing helped my family in our darkest PICU moments

Printout prescription drug information shouldn’t go digital

Supreme Court strikes down use of affirmative action

The woman behind the Dana Farber

Supreme Court strikes down use of affirmative action

Pumping milk in bathrooms at health conferences is common

Psychedelics group wrestles with new pharma identity

Head of FDA's diagnostics center, who led through Covid, retires

Wikipedia

Congenital heart disease patients face new threat of heart failure

STAT letters to the editor on burnt

Inaction leaves children at risk from dangerous chemotherapy drug

FDA endorses new sterilization method for medical devices

Roche to buy Carmot Therapeutics, developer of obesity drugs

Patients' immediate access to test results puts radiologists in a bind

leisure time

hotspot

entertainment

knowledge